IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials

iOmx Therapeutics AG has received regulatory approval from the Spanish Agency of Medicines and Medicinal Products for its Clinical Trial Application for IOMX-0675. This marks a significant step for iOmx, a biopharmaceutical company focused on developing innovative cancer therapies. The approved Phase I/IIa clinical trial will evaluate the safety, tolerability, and preliminary efficacy of IOMX-0675 in treating various solid tumors.

IOMX-0675 is a LILRB1/LILRB2-dual-targeting antibody, designed to selectively block immunosuppressive receptors in myeloid and lymphoid cells, potentially enhancing immune response against tumors. Preclinical data indicate its potential as a best-in-class treatment for solid tumors, including colorectal, non-small cell lung, and gastric cancers.

iOmx's commitment to developing therapies with single-agent activity and multi-modal mechanisms underscores its dedication to addressing cancers resistant to current treatments. The company's CEO and CMO highlight the promise of IOMX-0675 in yielding effective cancer therapies.